Blockchain Registration Transaction Record

Clene Advances CNM-Au8® for ALS, Eyes 2025 FDA Submission

Clene Inc. updates on CNM-Au8® for ALS, targeting FDA NDA submission in 2025. Learn about their clinical progress and impact on neurodegenerative diseases.

This development is crucial because ALS is a progressive and fatal neurodegenerative disease with limited treatment options, affecting thousands of patients globally. If approved, CNM-Au8® could offer a novel therapeutic approach that improves mitochondrial function and neuronal survival, potentially slowing disease progression and enhancing quality of life. For investors and the biopharmaceutical industry, Clene's progress signifies innovation in tackling challenging diseases, while patients and families gain hope for more effective treatments amid high unmet medical needs.